HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Ala(2)-Cys(6)- enkephalin-Leu
affinity label for delta-opiate receptors
Also Known As:
enkephalin-Leu, Ala(2)-Cys(6)-; 2-Ala-6-Cys-Leu-enkephalin; DALCE; Leu-enkephalin, Ala(2)-Cys(6)-; enkephalin-Leu, alanyl(2)-cysteine(6)-; leucine-enkephalin, Ala(2)-Cys(6)-
Networked:
5
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Nerve Tissue Proteins: 2
Neuropeptides: 6772
Opioid Peptides: 1339
Enkephalins: 1042
Leucine Enkephalin: 304
Leucine-2-Alanine Enkephalin: 135
Ala(2)-Cys(6)- enkephalin-Leu: 5
Peptides: 82426
Neuropeptides: 6772
Opioid Peptides: 1339
Enkephalins: 1042
Leucine Enkephalin: 304
Leucine-2-Alanine Enkephalin: 135
Ala(2)-Cys(6)- enkephalin-Leu: 5
Related Diseases
1.
Hyperphagia (Overeating)
06/01/1991 - "
Hyperphagia following exposure to a high-fat diet was significantly potentiated by long-term DALCE (1 microgram) pretreatment.
"
06/01/1991 - "
2-Deoxy-D-glucose (650 mg/kg, IP) hyperphagia was transiently (2 h) decreased by long-term DALCE (10 micrograms) pretreatment.
"
06/01/1991 - "
DALCE (10 micrograms) hyperphagia (2-10 h) was eliminated by central pretreatment with either naltrexone (20 micrograms) or the kappa antagonist, nor-binaltorphamine (20 micrograms) but was minimally affected by central pretreatment with the mu antagonist, beta-funaltrexamine (20 micrograms) or long-term DALCE (40 micrograms).
"
03/01/1997 - "
Delt II-induced hyperphagia was significantly reduced by DALCE and NTII, but not naltrexone.
"
03/01/1997 - "
DPDPE-induced hyperphagia was significantly reduced by naltrexone and NTII, but not DALCE.
"
2.
Body Weight (Weight, Body)
06/01/1991 - "
DALCE (10 micrograms) significantly stimulated free feeding for up to 10 h but only minimally decreased (40 micrograms) food intake and body weight after 24-72 h.
"
01/01/1997 - "
Body weight and food intake are significantly reduced in rats during development of dietary obesity following chronic central administration of mu (beta-funaltrexamine, BFNA), mu1 (naloxonazine), kappa1 (nor-binaltorphamine, NBNI), delta1 ([D-Ala2,Leu5,Cys6]-enkephalin, DALCE) and delta2 (naltrindole isothiocyanate, NTII) opioid receptor subtype antagonists.
"
3.
Pain (Aches)
02/19/1990 - "
DALCE (0.4-10 micrograms) administered i.c.v. 24 h earlier failed to affect baseline pain sensitivity.
"
4.
Obesity
01/01/1997 - "
Body weight and food intake are significantly reduced in rats during development of dietary obesity following chronic central administration of mu (beta-funaltrexamine, BFNA), mu1 (naloxonazine), kappa1 (nor-binaltorphamine, NBNI), delta1 ([D-Ala2,Leu5,Cys6]-enkephalin, DALCE) and delta2 (naltrindole isothiocyanate, NTII) opioid receptor subtype antagonists.
"
5.
Body Weight Changes
06/01/1991 - "
DALCE, administered prior to food deprivation (24 h), failed to affect subsequent 24-h intake and sporadically decreased intake and body weight change after 48-72 h.
"
Related Drugs and Biologics
1.
Naltrexone (ReVia)
2.
beta-funaltrexamine
3.
Enkephalins
4.
naltrindole
5.
isothiocyanic acid
6.
D-Penicillamine (2,5)- Enkephalin
7.
Narcotic Antagonists (Opioid Antagonists)
8.
Ala(2)- deltorphin II
9.
deltorphin
10.
Opioid Receptors (Opioid Receptor)